日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Key vaccine in high demand, but supplies short

By LIU ZHIHUA | China Daily | Updated: 2019-07-05 07:08
Share
Share - WeChat
A woman has a 9-valent vaccine shot in Zhengzhou, capital of Henan province. Each year, some 131,500 new cervical cancer cases are reported in China, and about 53,000 patients die from the disease. ZHANG TAO/FOR CHINA DAILY

Once people can acquire the vaccination on a regular basis, the balance between supply and demand will be gradually restored, he said.

According to a report released earlier this year by Horizon Insights, a consultancy in Shanghai, some 300 million Chinese are in the recommended age group for the 2-valent vaccine, 130 million for the 4-valent, and 90 million for the 9-valent. Every year, 8 million people fall into the recommended age group for each vaccine.

Last year, 300,000 people were vaccinated with the 2-valent type, 1.1 million with the 4-valent, and only 100,000 with the 9-valent, resulting in market values of 500 million yuan, 2.7 billion yuan and 400 million yuan, the report said.

About 833,300 doses of the 2-valent vaccine, 3.41 million of the 4-valent and 1.22 million of the 9-valent were released on the market last year, according to the report.

It estimated that the market value for the 2-, 4-and 9-valent vaccines would reach 1 billion yuan, 7.2 billion yuan and 10 billion in times of peak demand.

There will continue to be a shortage of all three types until next year, as the huge demand that exists now cannot be met in a short period, the report said.

Zhao Heng, founder of consulting company Latitude Health, said the shortage could be resolved through increased production and distribution, but as the three types of vaccine are not on the national compulsory vaccination program, it is difficult for the authorities to order pharmaceutical companies to increase supplies.

However, more than a dozen Chinese pharmaceutical companies are developing HPV vaccines ranging from 2-valent to 14-valent, and some have started phase-3 clinical trials while others have only just received approval for such trials, according to the Horizon Insights report.

|<< Previous 1 2 3 4   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 操舔 | 亚洲国产精品99久久久久久久久 | 最新欧美精品一区二区三区 | 色综合免费 | 香蕉久久久久久 | 欧美精品在线视频观看 | 天天摸天天爽视频69视频 | a黄在线观看 | 天天做天天爱天天操 | 国产一区中文字幕 | 久久精品男人 | 久久99综合国产精品亚洲首页 | 国产精品一区在线观看你懂的 | 日韩欧美三级在线 | 一区二区在线不卡 | 欧美激情视频一区二区三区在线播放 | 精品av| 大陆黄色a级片 | 久久久久久久久女黄 | 一区二区不卡在线观看 | 黄色视频a级毛片 | 美女扒开胸罩给男生看视频 | 国产精品人妻无码久久久2022 | 国产免费又色又爽又黄的网站 | 久久久www成人免费精品张筱雨 | 国产黄色2 | 亚洲免费在线看 | 免费看a | 亚洲人成在线精品 | 91免费版成人 | 国产高清在线精品免费 | 欧美在线观看视频一区 | 久久免费看少妇高潮A片特黄多 | 哪里看毛片 | 青青久视频 | 色噜噜狠狠先锋影音久久 | 性少妇videosexfreexx | 国产福利不卡视频在免费播放 | 国产精品久久久久久搜索 | 日本一级淫片免费看 | theporn国产在线精品 |